亿帆医药：全资子公司在研产品N-3C01注射液获得临床试验批准通知书

Core Viewpoint - The company Yifan Pharmaceutical (002019.SZ) announced that its wholly-owned subsidiary Hefei Xinzhu Biotechnology Co., Ltd. has received approval from the National Medical Products Administration for the clinical trial of the innovative macromolecule drug N-3C01 injection, aimed at treating advanced solid tumors and non-muscle invasive bladder cancer [1] Group 1 - The N-3C01 drug is a recombinant IL-15/IL-15Rα fusion protein developed using DNA recombinant technology, which can activate the proliferation and killing functions of NK cells and cytotoxic T cells to achieve immune activation for tumor eradication [1] - As of the announcement date, similar target drugs have been approved in the United States and the United Kingdom, while no products targeting the same pathway have been approved for market in China [1] - The development and production cycle for this drug is long and involves multiple stages, leading to uncertainty regarding future approval for market release by the National Medical Products Administration [1]